Bristol wins U.S. approval for single anti-HIV pill


NEW YORK (Reuters) - Bristol-Myers Squibb Co. said on Friday that U.S. regulators approved a single-capsule form of its Reyataz HIV drug to be taken as part of combination drug therapy.

Taken once a day, the 300 milligram Reyataz can replace two 150 mg capsules of the drug and will be available within a week, the company said.